However, a poorer prognosis in cPAN may be associated with factors such as pretreatment ulcer status, neutrophil to lymphocyte ratio, C-reactive protein level, and the immune systemic inflammation index[25] or comorbidities, such as PAH.[26]. This evidence concerns the gene CRP and pulmonary arterial hypertension.